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Abstract 
We report the case of a young woman with hereditary hemorrhagic telangiectasia (HHT) with 
severe liver involvement and pulmonary shunting. The medical imaging in this patient illus-
trates the severe shunting that can occur in these patients who often are asymptomatic. By 
showing this case, we want to highlight the role of liver transplantation in HHT with hepatic 
involvement. © 2018 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Hereditary hemorrhagic telangiectasia (HHT) is an inherited vascular disorder affecting 
1 in 5,000–8,000 people [1]. The disease is inherited as an autosomal dominant trait. HHT 
gene mutations are located in genes encoding proteins involved in the transforming growth 
factor (TGF)-β superfamily signaling in vascular endothelial cells, leading to the develop-
ment of abnormal vascular structures [2]. Clinical HHT presentation patterns vary widely 
among and within families, ranging from dilated microvessels to large arteriovenous mal-
formations (AVMs). These abnormalities can lead to anemia, recurrent epistaxis, and gastro-
intestinal blood loss [3, 4]. These patients develop AVMs of the pulmonary, hepatic, and cer-
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ebral circulation [2]. AVMs affect the majority of patients but often remain silent [5]. In a 
minority of patients, major complications can develop over time and include severe anemia 
from chronic nasal and gastrointestinal blood loss, stroke, deep venous thromboembolism, 
symptomatic liver disease, and severe pulmonary hypertension [6, 7].  
The genetic basis of the disease includes 3 genotypes. HHT type 1 results from muta-
tions in ENG encoding endoglin (chromosome 9) [8], HHT type 2 is the result of mutations in 
ACVRL1 encoding ALK1 (chromosome 12) [9], and HHT in association with juvenile polypo-
sis results from mutations in MADH4 (chromosome 18) [10]. Two other unidentified genes 
have been related to HHT development, HHT3 and HHT4 [11, 12].  
The clinical diagnosis of HHT is based on the presence of at least 3 of the “Curaçao crite-
ria,” including spontaneous recurrent nosebleeds, mucocutaneous telangiectasia, visceral 
involvement, or a first-degree family history of HHT [3]. After the diagnosis of HHT, clinical 
workup should include a detailed family history, referring the patient with particular prob-
lems to an organ-specific specialist with experience in HHT, screening for asymptomatic 
AVMs, formalizing the diagnosis of HHT, which may include molecular testing, and providing 
information and opportunity for follow-up and family screening [2]. 
Case Report 
This 36-year-old woman who suffered from recurrent epistaxis since her childhood was 
referred due to elevated liver enzymes (bilirubin 1.8 mg/dL, AST 143 U/L, ALT 90 U/L, GGT 
1,060 U/L, and AF 366 U/L). She reported no specific complaints. At clinical examination, a 
vascular sound could be heard in the epigastric region at auscultation. Abdominal ultraso-
nography with duplex showed multiple large vascular structures in the liver. The importance 
of these vascular malformations was confirmed using a CT scan. A coronal maximum intensi-
ty projection image (arterial phase; Fig. 1) showed large, tortuous extrahepatic and intrahe-
patic arteries (black arrows) and diffuse punctate telangiectasias in the liver parenchyma 
(white arrowheads). Also, 2 pulmonary AVMs were noted in the left upper and right lower 
lobe (white arrows). Three-dimensional volume-rendered arterial phase image (Fig. 2) 
showed early opacification of the hepatic veins (white arrows) secondary to arteriovenous 
shunting, also illustrated by the axial arterial (Fig. 3a) and hepatic (Fig. 3b) phase images. 
Note the numerous telangiectasias (arrowheads and brace). 
The clinical suspicion of a Rendu-Osler-Weber syndrome was confirmed by genetic 
analysis which confirmed a c.430C>T (p.arg144*) mutation in the ALK1 gene. Echocardiog-
raphy revealed a mild pulmonary hypertension (gradient 45–55 mm Hg, central venous 
pressure 10–15 mm Hg) with a mild concentric remodeling of the right ventricular wall. Due 
to the pulmonary hypertension, the patient will be considered for liver transplantation. 
Discussion 
HHT or Rendu-Osler-Weber disease is an autosomal dominant dysplasia characterized 
by widespread cutaneous, mucosal, and visceral telangiectasias [3, 13]. These telangiecta-
sias, the hallmark of the disease, arise from the dilatation of postcapillary venules which 
directly fuse with an arteriole, thus bypassing the capillary system [14]. The clinical presen-
tation can vary from mild to very extensive. Complications occur when visceral organs are 
affected, such as the brain, the lungs, and the liver [15].  
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Liver involvement can be discrete and limited to vascular derangements on a micro-
scopical level and can range to large direct shunts between the hepatic arteriolar branches 
and sinusoids (leading to arteriovenous shunts), between the portal vein and the central 
veins (portovenous shunts), and between the hepatic artery and the portal vein [14]. Our 
patient suffered from the first scenario. These hepatic malformations can lead to liver en-
largement and (peri)portal fibrosis and a noncirrhotic nodular transformation of the liver 
[16]. An increased number of focal nodular hyperplasias have been witnessed in these pa-
tients [17].  
Patients with HHT are generally asymptomatic [18]. The main risk of large arteriove-
nous shunting is the development of high-output congestive heart failure [14, 15, 19]. Thus, 
once diagnosis of hepatic involvement in HHT is established, periodical echocardiography is 
advised [14]. In the presence of arterioportal shunts, portal hypertension can develop, and 
upper gastrointestinal endoscopy should be performed in order to detect esophageal varices 
[14]. Some patients will develop an anicteric cholestasis, which can lead to severe cholestasis 
and sepsis in rare cases [14].  
Liver transplantation can be the only definitive curative option for patients with HHT 
with advanced hepatic involvement [19]. The main indications for liver transplantation are 
high-output cardiac failure, severe portal hypertension, and extended biliary necrosis [19]. 
Outcome after liver transplantation is excellent, with a 10-year patient and graft survival 
rate of 83% [19]. Recurrence of the disease after liver transplantation has been reported in 2 
patients [20]. 
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Fig. 1. Coronal maximum intensity projection image obtained in the arterial phase shows large, tortuous 
extrahepatic and intrahepatic arteries (black arrows) and diffuse punctate telangiectasias in the liver pa-
renchyma (white arrowheads). Also note 2 pulmonary arteriovenous malformations in the left upper and 




Fig. 2. Hepatic lesions in a 36-year-old woman with hereditary hemorrhagic telangiectasia. Three-
dimensional volume-rendered arterial phase image shows early opacification of the hepatic veins (white 
arrows) secondary to arteriovenous shunting. Note the numerous telangiectasias (arrowheads and brace). 
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Fig. 3. Axial arterial (a) and hepatic (b) phase images show a large arteriovenous shunt in the right lobe 
(black arrow) and multiple focal nodular hyperplasias (white arrows). 
 
